Get the Stockscreener App
281.38
1.00%
2.79
After Hours:
280.66
-0.72
-0.26%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $281.38, with a volume of 898.48K.
It is up +1.00% in the last 24 hours and up +1.56% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$278.59
Open:
$279.35
24h Volume:
898.48K
Relative Volume:
0.92
Market Cap:
$41.20B
Revenue:
$5.15B
Net Income/Loss:
$1.40B
P/E Ratio:
29.59
EPS:
9.5082
Net Cash Flow:
$1.65B
1W Performance:
+3.81%
1M Performance:
+1.56%
6M Performance:
+37.14%
1Y Performance:
+20.26%
1-Day Range:
$278.32
$283.04
1-Week Range:
$267.64
$283.04
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
281.38 | 40.66B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ISRG
Intuitive Surgical Inc
|
449.69 | 162.16B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
191.99 | 55.49B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
76.82 | 38.26B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
268.07 | 19.60B | 2.96B | 487.70M | 344.00M | 6.68 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Quantitative breakdown of ResMed Inc. recent moveVolume Spike & Weekly Watchlist for Consistent Profits - newser.com
Intraday pattern recognizer results for ResMed Inc.Quarterly Profit Review & Weekly High Potential Stock Alerts - newser.com
Will ResMed Inc. stock attract long term capital inflowsGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
How ResMed Inc. (Common Stock) (RMEA) stock benefits from digital adoptionTrade Entry Report & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for ResMed Inc.Market Performance Recap & Stock Portfolio Risk Management - newser.com
Will ResMed Inc. (Common Stock) (RMEA) stock benefit from mergersMarket Movement Recap & High Accuracy Swing Entry Alerts - newser.com
How ResMed Inc. stock reacts to job market dataTrade Volume Summary & Detailed Earnings Play Strategies - newser.com
Is a relief rally coming for ResMed Inc. holders2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Why ResMed Inc. (RME) stock remains stablePortfolio Risk Report & Intraday High Probability Alerts - newser.com
Chart overlay techniques for tracking ResMed Inc.Earnings Risk Report & Daily Growth Stock Tips - newser.com
Is ResMed Inc. (Common Stock) (RMEA) stock vulnerable to rate hikesJuly 2025 PreEarnings & Stock Portfolio Risk Control - newser.com
ResMed Insider Lowered Holding By 22% During Last Year - Yahoo
Will ResMed Inc. stock beat growth indexesEarnings Beat & Growth Focused Stock Reports - newser.com
How supply shortages influence ResMed Inc. (Common Stock) (RMEA) stock2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
ResMed Inc. Reports Increase in CHESS Depositary Interests for September 2025 - MSN
How strong is ResMed Inc. (RME) stock earnings growthDividend Hike & Low Risk Growth Stock Ideas - newser.com
Why retail investors favor ResMed Inc. stockBull Run & Safe Capital Growth Stock Tips - newser.com
What margin trends mean for ResMed Inc. stockBear Alert & Community Consensus Picks - newser.com
Published on: 2025-10-05 03:46:09 - newser.com
Can ResMed Inc. stock sustain revenue momentumRate Cut & Real-Time Volume Trigger Notifications - newser.com
Does ResMed Inc. (RME) stock trade below intrinsic value2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Why ResMed Inc. stock could outperform in 2025Portfolio Gains Report & Consistent Income Trade Ideas - newser.com
ResMed Inc. Announces 2025 Virtual Annual Meeting for Shareholder Engagement - MSN
What hedge fund moves indicate for ResMed Inc. (Common Stock) (RMEA) stockPortfolio Value Report & Risk Adjusted Swing Trade Ideas - newser.com
How sentiment analysis helps forecast ResMed Inc.2025 Top Decliners & Technical Confirmation Trade Alerts - newser.com
How ResMed Inc. (Common Stock) (RMEA) stock moves on employment dataJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Is ResMed Inc. (RME) stock a top hedge fund pick2025 Top Decliners & Daily Growth Stock Investment Tips - newser.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):